Skip to Main Content

Skip Nav Destination

PUB: Epidemiology—Type 1 Diabetes| June 01 2019

2462-PUB: Differences between Type 1 Diabetes Adults With and Without Lipid-Lowering Treatment

MARIA GEMMA RODRIGUEZ CARNERO;

MARIA GEMMA RODRIGUEZ CARNERO

Ferrol, Spain, Granada, Spain, A Coruña, Spain, Pamplona, Spain, Valencia, Spain, Oviedo, Spain, Seville, Spain, Lleida, Spain, Bilbao, Spain, Pontevedra, Spain, Barcelona, Spain, Málaga, Spain, Madrid, Spain

Search for other works by this author on:

PubMed

Google Scholar

DIEGO BELLIDO GUERRERO, SR.;

DIEGO BELLIDO GUERRERO, SR.

Ferrol, Spain, Granada, Spain, A Coruña, Spain, Pamplona, Spain, Valencia, Spain, Oviedo, Spain, Seville, Spain, Lleida, Spain, Bilbao, Spain, Pontevedra, Spain, Barcelona, Spain, Málaga, Spain, Madrid, Spain

Search for other works by this author on:

PubMed

Google Scholar

CRISTINA TEJERA;

CRISTINA TEJERA

Ferrol, Spain, Granada, Spain, A Coruña, Spain, Pamplona, Spain, Valencia, Spain, Oviedo, Spain, Seville, Spain, Lleida, Spain, Bilbao, Spain, Pontevedra, Spain, Barcelona, Spain, Málaga, Spain, Madrid, Spain

Search for other works by this author on:

PubMed

Google Scholar

MARTÍN LÓPEZ DE LA TORRE;

MARTÍN LÓPEZ DE LA TORRE

Ferrol, Spain, Granada, Spain, A Coruña, Spain, Pamplona, Spain, Valencia, Spain, Oviedo, Spain, Seville, Spain, Lleida, Spain, Bilbao, Spain, Pontevedra, Spain, Barcelona, Spain, Málaga, Spain, Madrid, Spain

Search for other works by this author on:

PubMed

Google Scholar

ALFONSO SOTO GONZÁLEZ, SR.;

ALFONSO SOTO GONZÁLEZ, SR.

Ferrol, Spain, Granada, Spain, A Coruña, Spain, Pamplona, Spain, Valencia, Spain, Oviedo, Spain, Seville, Spain, Lleida, Spain, Bilbao, Spain, Pontevedra, Spain, Barcelona, Spain, Málaga, Spain, Madrid, Spain

Search for other works by this author on:

PubMed

Google Scholar

FRANCISCO J. ESCALADA;

FRANCISCO J. ESCALADA

Ferrol, Spain, Granada, Spain, A Coruña, Spain, Pamplona, Spain, Valencia, Spain, Oviedo, Spain, Seville, Spain, Lleida, Spain, Bilbao, Spain, Pontevedra, Spain, Barcelona, Spain, Málaga, Spain, Madrid, Spain

Search for other works by this author on:

PubMed

Google Scholar

ANTONIO HERNANDEZ-MIJARES, SR.;

ANTONIO HERNANDEZ-MIJARES, SR.

Ferrol, Spain, Granada, Spain, A Coruña, Spain, Pamplona, Spain, Valencia, Spain, Oviedo, Spain, Seville, Spain, Lleida, Spain, Bilbao, Spain, Pontevedra, Spain, Barcelona, Spain, Málaga, Spain, Madrid, Spain

Search for other works by this author on:

PubMed

Google Scholar

LORENA SUAREZ GUTIERREZ, SR.;

LORENA SUAREZ GUTIERREZ, SR.

Ferrol, Spain, Granada, Spain, A Coruña, Spain, Pamplona, Spain, Valencia, Spain, Oviedo, Spain, Seville, Spain, Lleida, Spain, Bilbao, Spain, Pontevedra, Spain, Barcelona, Spain, Málaga, Spain, Madrid, Spain

Search for other works by this author on:

PubMed

Google Scholar

CRISTOBAL MORALES, SR.;

CRISTOBAL MORALES, SR.

Ferrol, Spain, Granada, Spain, A Coruña, Spain, Pamplona, Spain, Valencia, Spain, Oviedo, Spain, Seville, Spain, Lleida, Spain, Bilbao, Spain, Pontevedra, Spain, Barcelona, Spain, Málaga, Spain, Madrid, Spain

Search for other works by this author on:

PubMed

Google Scholar

LILIANA GUTIÉRREZ CARRASQU, SR.;

LILIANA GUTIÉRREZ CARRASQU, SR.

Ferrol, Spain, Granada, Spain, A Coruña, Spain, Pamplona, Spain, Valencia, Spain, Oviedo, Spain, Seville, Spain, Lleida, Spain, Bilbao, Spain, Pontevedra, Spain, Barcelona, Spain, Málaga, Spain, Madrid, Spain

Search for other works by this author on:

PubMed

Google Scholar

AIDA CADENAS;

AIDA CADENAS

Ferrol, Spain, Granada, Spain, A Coruña, Spain, Pamplona, Spain, Valencia, Spain, Oviedo, Spain, Seville, Spain, Lleida, Spain, Bilbao, Spain, Pontevedra, Spain, Barcelona, Spain, Málaga, Spain, Madrid, Spain

Search for other works by this author on:

PubMed

Google Scholar

OLAIA DÍAZ TRASTOY;

OLAIA DÍAZ TRASTOY

Ferrol, Spain, Granada, Spain, A Coruña, Spain, Pamplona, Spain, Valencia, Spain, Oviedo, Spain, Seville, Spain, Lleida, Spain, Bilbao, Spain, Pontevedra, Spain, Barcelona, Spain, Málaga, Spain, Madrid, Spain

Search for other works by this author on:

PubMed

Google Scholar

JUDIT AMIGÓ-FARRAN;

JUDIT AMIGÓ-FARRAN

Ferrol, Spain, Granada, Spain, A Coruña, Spain, Pamplona, Spain, Valencia, Spain, Oviedo, Spain, Seville, Spain, Lleida, Spain, Bilbao, Spain, Pontevedra, Spain, Barcelona, Spain, Málaga, Spain, Madrid, Spain

Search for other works by this author on:

PubMed

Google Scholar

INMA GONZALEZ MOLERO;

INMA GONZALEZ MOLERO

Ferrol, Spain, Granada, Spain, A Coruña, Spain, Pamplona, Spain, Valencia, Spain, Oviedo, Spain, Seville, Spain, Lleida, Spain, Bilbao, Spain, Pontevedra, Spain, Barcelona, Spain, Málaga, Spain, Madrid, Spain

Search for other works by this author on:

PubMed

Google Scholar

VIRGINIA BELLIDO;

VIRGINIA BELLIDO

Ferrol, Spain, Granada, Spain, A Coruña, Spain, Pamplona, Spain, Valencia, Spain, Oviedo, Spain, Seville, Spain, Lleida, Spain, Bilbao, Spain, Pontevedra, Spain, Barcelona, Spain, Málaga, Spain, Madrid, Spain

Search for other works by this author on:

PubMed

Google Scholar

FRANCISCO ARRIETA;

FRANCISCO ARRIETA

Ferrol, Spain, Granada, Spain, A Coruña, Spain, Pamplona, Spain, Valencia, Spain, Oviedo, Spain, Seville, Spain, Lleida, Spain, Bilbao, Spain, Pontevedra, Spain, Barcelona, Spain, Málaga, Spain, Madrid, Spain

Search for other works by this author on:

PubMed

Google Scholar

FRANCISCO TINAHONES;

FRANCISCO TINAHONES

Ferrol, Spain, Granada, Spain, A Coruña, Spain, Pamplona, Spain, Valencia, Spain, Oviedo, Spain, Seville, Spain, Lleida, Spain, Bilbao, Spain, Pontevedra, Spain, Barcelona, Spain, Málaga, Spain, Madrid, Spain

Search for other works by this author on:

PubMed

Google Scholar

A DE ENDOCRINOLOGÍA Y NUTRICIÓN GRUPO DE TRABAJO DE LÍPIDOS DE LA SOCIEDAD ESPAÑOL

A DE ENDOCRINOLOGÍA Y NUTRICIÓN GRUPO DE TRABAJO DE LÍPIDOS DE LA SOCIEDAD ESPAÑOL

Search for other works by this author on:

PubMed

Google Scholar

Diabetes 2019;68(Supplement_1):2462-PUB

https://doi.org/10.2337/db19-2462-PUB

Introduction: Cardiovascular disease (CVD) is the major cause of mortality in T1D. Lipid-lowering treatment (LLT) with statins prevent major cardiovascular events and dead in a broad spectrum of patients. However, evidence of CVD risks factors and its management are based on subgroup analyses and extrapolations of effects demonstrates in other populations.

Objectives: The aim of the study was to analyze the differences between T1D adults on lipid-lowering treatment (T group) and without treatment (No T group). We pay special attention to CVD risk factors, comorbidities and which factors are associated with receiving lipid-lowering treatment.

Research design and Methods: A multicentric, cross-sectional study in Spain included 1252 T1D adults who visited Diabetes Clinic from December 2017 to December 2018.

Results: Among 1252 patients 344 were on LLT. In terms of lipid profile LDL (131 vs. 100 mg/dL), HDL (57 vs. 60 mg/dL), total cholesterol (213 vs. 178 mg/dL) and triglycerides (125 vs. 85 mg/dL) levels were statistically significant while compared between T and No T groups. T group was older (48 vs. 37 years old) and the median duration of diabetes was higher (25 vs. 18 years)than No T group (p< 0.000). BMI in T group was 27 kg/m² higher than no T group (25 kg/m²) (p < 0,0001). There was a trend toward higher prevalence of microvascular (57% vs. 23,8%) and macrovascular complications (13,7% vs. 3,6%) in T group than in No T (p < 0,000). A positive association was found between sex (male), smoking, high blood pressure and to be on treatment. There were no differences between the T group and No T group in terms of A1c (A1c 7,90% vs. 7,99%) or fasting glucose (157 vs.161 mg/dl).

Conclusions: This multicentric study shows that starting LLT is associated with LDL > 100 mg/dL, aged, sex (male), duration of diabetes, high BMI, comorbidities, smoking and a high blood pressure. Our results show compliance with the recommendations of 2014 AHA/ADA scientific statement type 1 diabetes mellitus and Cardiovascular Disease.

Disclosure

M. Rodriguez Carnero: None. D. Bellido Guerrero: None. C. Tejera: None. M. López de la Torre: None. A. Soto González: None. F.J. Escalada: Advisory Panel; Self; Merck Sharp & Dohme Corp., Novo Nordisk A/S, Sanofi. Consultant; Self; Esteve, Lilly Diabetes. Speaker's Bureau; Self; Amgen Inc., AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Janssen Pharmaceuticals, Inc., Merck Sharp & Dohme Corp., Novo Nordisk A/S, Sanofi. A. Hernandez-Mijares: None. L. Suarez Gutierrez: None. C. Morales: Other Relationship; Self; AstraZeneca, Janssen Pharmaceuticals, Inc., Lilly Diabetes, Merck Sharp & Dohme Corp., Novo Nordisk A/S, Sanofi. L. Gutiérrez Carrasqu: None. A. Cadenas: Advisory Panel; Self; Janssen Pharmaceuticals, Inc. O. Díaz Trastoy: None. J. Amigó-Farran: None. I. Gonzalez molero: None. V. Bellido: None. F. Arrieta: None. F. Tinahones: Advisory Panel; Self; Lilly Diabetes, Novo Nordisk A/S, Regeneron Pharmaceuticals, Sanofi-Aventis. Consultant; Self; AstraZeneca. Research Support; Self; AstraZeneca. Speaker's Bureau; Self; Danone Nutricia Research, Lilly Diabetes, Novo Nordisk A/S, Regenerative Medical Solutions, Sanofi-Aventis.

© 2019 by the American Diabetes Association.

2019

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.